Main Content
latest…
Sell Promis Neurosciences, Mackie Research says
An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his … Keep reading
More recent headlines
Cannabis
Curaleaf Holdings still has loads of upside, GMP Securities says
US cannabis company Curaleaf Holdings (Curaleaf Holdings Stock Quote, Chart CSE:CURA) is showing solid execution during its rapid build-out, says GMP … Read More
See related
Stock Picks
Sell Promis Neurosciences, Mackie Research says
An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his rating for Promis Neurosciences (Promis … Read more
See related
Life Sciences Stocks
Sell Promis Neurosciences, Mackie Research says
An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his … Keep reading
IMV has a 49 per cent upside, Mackie Research says
Biotech company IMV (IMV Stock Quote, Chart TSX:IMV) got a target reduction Friday from Mackie … Keep reading
Cipher Pharma has a huge upside, says Echelon Wealth
Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of … Keep reading
Aurinia Pharma has a 56 per cent upside, Mackie Research says
Mackie Research analyst André Uddin is bullish on Canadian drug development company Aurinia … Keep reading
Cipher Pharmaceuticals has a 155 per cent upside, Mackie Research says
Expect top line growth to reaccelerate for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock … Keep reading